Wize Pharma Inc., of Hod Hasharon, Israel, closed a private placement resulting in gross proceeds of $4.45 million. Proceeds from the financing will enable the company to advance the development of its lead product, LO2A, including completing trials and supporting the company's international marketing strategy with local territorial distributors.